explore -WSS

explore

author：focus 2025-09-27 12:48:36 - browse：5

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： Questions loom on AstraZeneca cancer drug as safety concerns ebb

WSS

Health tech investors get more selective as pandemic boom fades

Roche acquires Telavant from Roivant, adding experimental IBD treatment

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Results on Novartis prostate cancer therapy could expand its use

Questions loom on AstraZeneca cancer drug as safety concerns ebb

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

entertainment

explore

focus

Trump demands the U.S. pay no more for drugs than other countries … again

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Duchenne breakthrough therapy leaves behind pioneering families

J&J lung cancer data amount to new salvo against AstraZeneca

Heart attack and stroke risk calculators need revising

Readout LOUD podcast: Live from the 2023 STAT Summit

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Medicare drug price negotiation hasn't dried up venture capital

Walensky prepares to leave CDC — and Congress — behind

CZI to create biohub to build anti

hotspot

Editas, Vertex strike deal on CRISPR

Keeping primary care docs in field isn't impossible, says AAFP CEO

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Editas, Vertex strike deal on CRISPR

FDA clears Verve to begin U.S. study of gene

CZI to create biohub to build anti

Wikipedia

entertainment

entertainment

leisure time